In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
The price of Thermo Fisher Scientific Inc (NYSE: TMO) closed at $585.15 in the last session, down -0.96% from day before closing price of $590.83. In other words, the price has decreased by -$0.96 from its previous closing price. On the day, 1.75 million shares were traded. TMO stock price reached its highest trading level at $597.2 during the session, while it also had its lowest trading level at $582.76.
Ratios:
We take a closer look at TMO’s different ratios to gain a better understanding of the stock. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 61.88 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 35.98. For the most recent quarter (mrq), Quick Ratio is recorded 1.11 and its Current Ratio is at 1.50. In the meantime, Its Debt-to-Equity ratio is 0.70 whereas as Long-Term Debt/Eq ratio is at 0.62.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Dec 01 ’25 when Lowery Frederick M. bought 6,913 shares for $597.68 per share.
Shafer Michael D sold 10,725 shares of TMO for $6,435,000 on Nov 25 ’25. The Executive Vice President now owns 18,731 shares after completing the transaction at $600.00 per share. On Nov 25 ’25, another insider, Shafer Michael D, who serves as the Officer of the company, bought 10,725 shares for $600.00 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TMO now has a Market Capitalization of 219845574656 and an Enterprise Value of 252115566592. As of this moment, Thermo’s Price-to-Earnings (P/E) ratio for their current fiscal year is 33.81, and their Forward P/E ratio for the next fiscal year is 23.78. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 4.55. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.03 while its Price-to-Book (P/B) ratio in mrq is 4.31. Its current Enterprise Value per Revenue stands at 5.764 whereas that against EBITDA is 23.269.
Stock Price History:
The Beta on a monthly basis for TMO is 0.90, which has changed by 0.094925284 over the last 52 weeks, in comparison to a change of 0.12607694 over the same period for the S&P500. Over the past 52 weeks, TMO has reached a high of $610.97, while it has fallen to a 52-week low of $385.46. The 50-Day Moving Average of the stock is 6.75%, while the 200-Day Moving Average is calculated to be 21.89%.
Shares Statistics:
According to the various share statistics, TMO traded on average about 2.02M shares per day over the past 3-months and 1605620 shares per day over the past 10 days. A total of 375.71M shares are outstanding, with a floating share count of 374.87M. Insiders hold about 0.22% of the company’s shares, while institutions hold 91.79% stake in the company. Shares short for TMO as of 1763078400 were 5462612 with a Short Ratio of 2.70, compared to 1760486400 on 3908166. Therefore, it implies a Short% of Shares Outstanding of 5462612 and a Short% of Float of 1.46.
Dividends & Splits
The forward annual dividend rate for TMO is 1.68, which was 1.68 in the trailing 12 months. Against a Trailing Annual Dividend Yield of 0.0028434573. The stock’s 5-year Average Dividend Yield is 0.24. The current Payout Ratio is 9.43% for TMO, which recently paid a dividend on 2025-09-15 with an ex-dividend date of 2025-12-15. Stock splits for the company last occurred on 1996-06-06 when the company split stock in a 3:2 ratio.
Earnings Estimates
The dynamic stock of Thermo Fisher Scientific Inc (TMO) is currently being evaluated by a team of 20.0 analysts, each contributing to its current rating.The consensus estimate for the next quarter is $5.6, with high estimates of $5.84 and low estimates of $5.38.
Analysts are recommending an EPS of between $22.81 and $22.51 for the fiscal current year, implying an average EPS of $22.73. EPS for the following year is $24.64, with 26.0 analysts recommending between $25.87 and $24.0.
Revenue Estimates
According to 18 analysts,. The current quarter’s revenue is expected to be $11.95B. It ranges from a high estimate of $12.01B to a low estimate of $11.82B. As of. The current estimate, Thermo Fisher Scientific Inc’s year-ago sales were $11.39BFor the next quarter, 18 analysts are estimating revenue of $11.03B. There is a high estimate of $11.25B for the next quarter, whereas the lowest estimate is $10.87B.
A total of 24 analysts have provided revenue estimates for TMO’s current fiscal year. The highest revenue estimate was $44.44B, while the lowest revenue estimate was $43.71B, resulting in an average revenue estimate of $44.26B. In the same quarter a year ago, actual revenue was $42.88BBased on 24 analysts’ estimates, the company’s revenue will be $46.51B in the next fiscal year. The high estimate is $46.93B and the low estimate is $46.01B.
